Ontology highlight
ABSTRACT:
SUBMITTER: Perez-Lloret S
PROVIDER: S-EPMC6183186 | biostudies-literature | 2015 Mar
REPOSITORIES: biostudies-literature
Perez-Lloret Santiago S Flabeau Olivier O Fernagut Pierre-Olivier PO Pavy-Le Traon Anne A Rey María Verónica MV Foubert-Samier Alexandra A Tison Francois F Rascol Olivier O Meissner Wassilios G WG
Movement disorders clinical practice 20150202 1
MSA is a progressive neurodegenerative disorder characterized by autonomic failure and a variable combination of poor levodopa-responsive parkinsonism and cerebellar ataxia (CA). Current therapeutic management is based on symptomatic treatment. Almost one third of MSA patients may benefit from l-dopa for the symptomatic treatment of parkinsonism, whereas physiotherapy remains the best therapeutic option for CA. Only midodrine and droxidopa were found to be efficient for neurogenic hypotension in ...[more]